Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)
CONCLUSIONS: We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall the prognosis of the disease is good, with excellent survival rates for all patients. Due to increased risk of associated HM, a long-term follow-up should be recommended for LyP patients.PMID:38595050 | DOI:10.1093/bjd/ljae150 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Ma ël Blanchard Marie-Anne Morren Anne-Marie Busschots Esther Hauben Silvia Alberti-Violetti Emilio Berti Gianluca Avallone Gianluca Tavoletti Michele Panzone Pietro Quaglino Cristiana Colonna Rutger C Melchers Maarten H Vermeer Robert Gniadecki Christin Source Type: research
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Leukemia, Published online: 10 April 2024; doi:10.1038/s41375-024-02246-2Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia (Source: Leukemia)
Source: Leukemia - April 10, 2024 Category: Hematology Authors: Harry Fruchtman Zachary M. Avigan Julian A. Waksal Nicole Brennan John O. Mascarenhas Source Type: research
Discovery of novel co-degradation CK1 α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
In this study, we designed and synthesized a series of novel PROTACs to reactivate p53 via the co-degradation of CK1α and CDK7/9 proteins. Bioactivity studies showed that the selected PROTAC 13i exhibited potency antiproliferative activity in MV4-11 (IC50 = 0.096 ± 0.012 μM) and MOLM-13 (IC50 = 0.072 ± 0.014 μM) cells, and induced apoptosis of MV4-11 cells. Western-blot analysis showed that PROTAC 13i triple CK1α and CDK7/9 protein degradation resulted in the significantly increased expression of p53. At the same time, the transcriptional repression due to the degradation significantly reduced downstream gene express...
Source: Bioorganic Chemistry - April 9, 2024 Category: Chemistry Authors: Kai Wang Meixu Jiang Huimin Liu Chen Meng Mengyuan Li Haibin Lu Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Discovery of novel co-degradation CK1 α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
In this study, we designed and synthesized a series of novel PROTACs to reactivate p53 via the co-degradation of CK1α and CDK7/9 proteins. Bioactivity studies showed that the selected PROTAC 13i exhibited potency antiproliferative activity in MV4-11 (IC50 = 0.096 ± 0.012 μM) and MOLM-13 (IC50 = 0.072 ± 0.014 μM) cells, and induced apoptosis of MV4-11 cells. Western-blot analysis showed that PROTAC 13i triple CK1α and CDK7/9 protein degradation resulted in the significantly increased expression of p53. At the same time, the transcriptional repression due to the degradation significantly reduced downstream gene express...
Source: Bioorganic Chemistry - April 9, 2024 Category: Chemistry Authors: Kai Wang Meixu Jiang Huimin Liu Chen Meng Mengyuan Li Haibin Lu Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy
ConclusionsIn this study, we observed treatment persistent MR leukemic subclones and their phenotypic changes during the treatment process of R/R AML patients. This underscores the importance of preemptive inhibition of clonal promiscuity in R/R AML, proposing a practical method for monitoring AML MR subclones. (Source: Cancer Medicine)
Source: Cancer Medicine - April 9, 2024 Category: Cancer & Oncology Authors: Dongchan Kim,
Sheehyun Kim,
Hyojin Song,
Daehyeon Gwak,
Suji Min,
Ja Min Byun,
Youngil Koh,
Junshik Hong,
Sung ‐Soo Yoon,
Hongseok Yun,
Dong‐Yeop Shin Tags: BRIEF COMMUNICATION Source Type: research
GSE197276 Identification of an RNA-binding region in 18S dimethyladenosine methyltransferase DIMT1 essential for proliferation of acute myeloid leukemia cells
Contributors : Kathy F Liu ; Julian Stoute ; Yulia Gonskikh ; Hui ShenSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensAberrant assembly and function of ribosomes are implicated in cancers, including acute myeloid leukemia (AML). Here, we find that 18S rRNA methyltransferase DIMT1 is essential for AML proliferation through a non-catalytic function. We demonstrate that a positively charged cleft on DIMT1 plays an important role in RNA binding. Mutations at the identified cleft (5mutA-DIMT1) significantly weakens binding of DIMT1 to rRNA in vitro and in cells. Strikingly, the ...
Source: GEO: Gene Expression Omnibus - April 9, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Other Homo sapiens Source Type: research
Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients
ConclusionA difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed administration of pegfilgrastim in these patients. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - April 9, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 1448: Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial
erzah M. Horton
Steven M. Kornblau
The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the Children’s Oncology Group phase 3 trial AAML1031 (NCT01371981). Proteasome inhibition influences the chromatin landscape and proteostasis, and we hypothesized that baseline proteomic analysis of histone- and chromatin-modifying enzymes (HMEs) would identify AML subgroups that benefitted from bortezomib addition. A proteomic profile of 483 patients treated with AAML1031 chemother...
Source: Cancers - April 9, 2024 Category: Cancer & Oncology Authors: Anneke D. van Dijk Fieke W. Hoff Yihua Qiu Stefan E. Hubner Robin L. Go Vivian R. Ruvolo Amanda R. Leonti Robert B. Gerbing Alan S. Gamis Richard Aplenc Edward A. Kolb Todd A. Alonzo Soheil Meshinchi Eveline S. J. M. de Bont Terzah M. Horton Steven M. Kor Tags: Article Source Type: research
CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications
Blood Cancer Journal, Published online: 09 April 2024; doi:10.1038/s41408-024-01042-6CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 9, 2024 Category: Hematology Authors: Fenghong Zhang Zhen Shen Jundan Xie Jingren Zhang Qian Wu Rui Jiang Xiangyu Zhao Xiaofei Yang Suning Chen Source Type: research
Low ‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
In conclusion, preliminary results indicated that low-dose venetoclax combined with azacitidine is effective and safe for the treatment of older and frail patients with newly diagnosed AML, providing a new treatment option for these patients.PMID:38586209 | PMC:PMC10996028 | DOI:10.3892/ol.2024.14362 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Chunmeng Rong Fang Yang Yalu Chen Ming Wang Cheng Ai Yuqing Luo Panpan Gao Yiqin Weng Xiaguang Huang Meier Gu Weiping Huang Yongming Xia Source Type: research
Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia
Oncotarget. 2024 Apr 8;15:248-254. doi: 10.18632/oncotarget.28579.ABSTRACTAcute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. This investigation examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorub...
Source: Oncotarget - April 8, 2024 Category: Cancer & Oncology Authors: Simonetta I Gaumond Rama Abdin Joel Costoya Andrew V Schally Joaquin J Jimenez Source Type: research
